肝细胞癌的免疫抑制肿瘤微环境与免疫治疗:现状与展望
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
肝细胞癌(HCC)是全球主要的健康问题,治疗方案有限,预后较差。
ALL SOURCES
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
肝细胞癌(HCC)是全球主要的健康问题,治疗方案有限,预后较差。
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE(FAP5/CD3), CAR-T cells, and immunotoxins in hep
这种高阶联合代表了一种针对肝细胞癌的新型多波次免疫治疗策略。
Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting.
近期在 ASCO 会议上公布的研究凸显了 HCC 治疗的进展,强调了持续创新的重要性。
An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma.
肝细胞癌(HCC)和胆管癌(CCA)构成原发性肝癌中高度恶性的类型。
Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors.
这些结果表明,GPC3 特异性 7sFv-T 细胞可能成为实体瘤的一种有前景的治疗策略。
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。